LEGEND
64 evidence topics · 10 sources
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Primary and secondary objectives in the statistical analysis plan
Objectives in the protocol: confirming the NATIVE glycemic effect and testing the empagliflozin combination
Rationale in the protocol for combining lanifibranor with an SGLT2 inhibitor
Proof-of-concept purpose and plans for the combination stated in the annual report
Location and study date
Registered locations
Planned sites in the protocol synopsis
Recruitment period, screening, and results posting in the ClinicalTrials.gov results
Interim analysis data cut-off and date in the statistical analysis plan
Study design
Three-arm design with an open-label combination arm in the protocol
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |
| Primary purpose | “Treatment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “39” |
Stratified randomization and sex quotas in the protocol
Rationale in the protocol for blinding the lanifibranor and placebo arms only
Interim analysis and stopping of recruitment
Treatment and follow-up periods in the poster
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record: cirrhosis, prior therapies, and BMI
Diagnosis of MASH by historical histology or noninvasive methods
Imaging definitions of NASH and the glycemic criterion in the protocol
Cirrhosis exclusion by biopsy or noninvasive criteria in the protocol
Other exclusion criteria in the protocol: weight change, NT-proBNP, renal function, and CYP2C8 interacting drugs
Autoimmune liver and thyroid disease exclusion following NATiV3 Data Monitoring Committee recommendations
Key inclusion criteria in the poster
Treatment
Treatment arms in the ClinicalTrials.gov record
Investigational treatments, dose adjustment, and interruption rules in the protocol
Background antidiabetic therapy, prohibited medications, and rescue medication in the protocol
Study outcomes
Rationale for using change in HbA1c as the primary endpoint
Primary endpoint as registered
Rationale: confirming the HbA1c decrease seen in NATIVE participants with type 2 diabetes
Rationale: shared metabolic pathways of NASH and type 2 diabetes
Secondary endpoints in the protocol: liver tests, glycemic response, body weight, and body composition
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and power calculation in the protocol
Treated participants in the full analysis set and participants in the primary MMRM analysis (registry)
Participants in the interim analysis
Description of analysis sets
Analysis sets defined in the statistical analysis plan
Hierarchical testing, type I error, and multiplicity in the protocol
Mixed model for repeated measures for the primary endpoint in the registry
Handling of intercurrent events in the poster
Results
Participant disposition
Participant flow by arm in the ClinicalTrials.gov results
“Started 12 13 14” (opens the source at this quote in a new tab)
“Completed 12 12 9” (opens the source at this quote in a new tab)
“Not Completed 0 1 5” (opens the source at this quote in a new tab)
“Adverse Event 0 1 0” (opens the source at this quote in a new tab)
“Lost to Follow-up 0 0 2” (opens the source at this quote in a new tab)
“Non compliance with study drug 0 0 1” (opens the source at this quote in a new tab)
“Withdrawal by Subject 0 0 2” (opens the source at this quote in a new tab)
Screening and reasons for non-randomization in the ClinicalTrials.gov results
Disposition by arm in the poster
Baseline characteristics
Demographics, glycemic stratum, and body size in the ClinicalTrials.gov baseline table
| Characteristic | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo | Total |
|---|---|---|---|---|
| Participants | “12 participants” | “13 participants” | “14 participants” | “39 participants” |
| Age, years, mean (SD) | “55.1(11.45)” | “54.2(13.48)” | “54.7(13.01)” | “54.6(12.38)” |
| Female, n | “6” | “8” | “7” | “21” |
| White, n | “10” | “10” | “9” | “29” |
| Hispanic or Latino, n | “7” | “4” | “7” | “18” |
| HbA1c ≥7.5%, n | “8” | “8” | “9” | “25” |
| Weight, kg, mean (SD) | “93.30(11.614)” | “103.30(12.437)” | “94.50(21.269)” | “97.06(16.213)” |
| BMI, kg/m2, mean (SD) | “33.34(2.282)” | “37.62(4.300)” | “34.54(5.442)” | “35.19(4.554)” |
Median baseline characteristics in the poster
| Characteristic | Lanifibranor | Lanifibranor plus empagliflozin | Placebo | Total |
|---|---|---|---|---|
| Age (years) | “55.5” | “54.0” | “55.5” | “55.0” |
| Sex (% female) | “6 (50)” | “8 (62)” | “7 (50)” | “21 (54)” |
| Country (% USA) | “11 (92)” | “12 (92)” | “12 (86)” | “35 (90)” |
| Weight (kg) | “93.9” | “99.9” | “97.4” | “97.2” |
| HbA1c (%) | “7.7” | “8.0” | “7.50” | “7.7” |
| ALT (U/L) | “53.0” | “52.0” | “33.0” | “39.0” |
| HOMA-IR | “9.4” | “10.9” | “16.3” | “10.8” |
| cT1 (ms) | “938” | “926” | “942” | “931” |
| MRI-PDFF (%) | “18.6” | “21.1” | “20.3” | “19.3” |
Efficacy results
Primary endpoint: absolute change in HbA1c from baseline to week 24, MMRM analysis (registry)
| Measure | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
|---|---|---|---|
| Participants analyzed | “11” | “13” | “13” |
| LS mean (95% CI) | “-1.11 (-1.6 to -0.62)” | “-1.54 (-2.02 to -1.06)” | “0.16 (-0.32 to 0.63)” |
Primary endpoint and HbA1c responders, FAS (poster)
HbA1c reduction and responders (company release, November 2024)
Primary endpoint and HbA1c responders at the interim analysis, FAS and completers (company release, March 2024)
| Interim analysis measure | Placebo | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg |
|---|---|---|---|
| HbA1c, LS mean absolute change from baseline to week 24 (%), FAS | “0.26” | “-1.14” | “-1.59” |
| Participants, FAS | “(n=9)” | “(n=11)” | “(n=10)” |
| HbA1c <6.5% at week 24 (%), completers | “0” | “55” | “63” |
| HbA1c absolute decrease ≥1% at week 24 (%), completers | “0” | “64” | “88” |
Hepatic steatosis by MRI-PDFF and cT1, LS mean change at week 24, FAS (poster)
Hepatic steatosis by MRI-PDFF at the interim analysis (company release, March 2024)
Secondary endpoints at week 24, LS mean (95% CI), MMRM or ANCOVA (registry)
| Outcome (unit) | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
|---|---|---|---|
| ALT, absolute change (U/L) | “-26.60 (-38.08 to -15.12)” | “-29.63 (-42.13 to -17.13)” | “-5.65 (-17.89 to 6.59)” |
| AST, absolute change (U/L) | “-13.67 (-20.66 to -6.68)” | “-17.81 (-25.5 to -10.12)” | “1.3 (-6.11 to 8.71)” |
| HOMA-IR, percentage change | “-50.79 (-95.69 to -5.89)” | “-45.23 (-89.86 to -0.61)” | “35.01 (-10.29 to 80.32)” |
| Insulin, percentage change | “-33.48 (-68.24 to 1.28)” | “-38.16 (-72.16 to -4.16)” | “10.17 (-23.63 to 43.96)” |
| Adiponectin, fold change | “2.87 (2.05 to 3.68)” | “3.03 (2.18 to 3.89)” | “1.24 (0.39 to 2.09)” |
| HDL cholesterol, relative change (%) | “16.48 (5.24 to 27.72)” | “15.30 (3.04 to 27.56)” | “2.55 (-9.76 to 14.86)” |
| VAT/SAT ratio, relative change (%) | “-4.6 (-14.44 to 5.25)” | “-17.45 (-28.67 to -6.23)” | “2.01 (-9.12 to 13.14)” |
Additional liver, fibrosis, inflammatory, and metabolic biomarkers, LS means at week 24 with p values (poster)
| LS mean at week 24 (p value versus placebo) | Lanifibranor | Lanifibranor plus empagliflozin | Placebo |
|---|---|---|---|
| GGT absolute change (IU/L) | “-21.9 (0.010)” | “-17.8 (0.015)” | “22.8” |
| TIMP-1 absolute change (ng/mL) | “-42.8 (0.040)” | “-40.0 (0.056)” | “-6.8” |
| Pro-C3 absolute change (ng/mL) | “-1.26 (0.120)” | “-3.54 (0.062)” | “7.33” |
| hs-CRP relative change (%) | “-32 (0.024)” | “-48 (0.008)” | “34” |
| Ferritin absolute change (µg/L) | “-78 (0.002)” | “-59 (0.022)” | “-8” |
| Glucose absolute change (mmol/L) | “-2.36 (0.005)” | “-1.98 (0.022)” | “-0.23” |
| Triglycerides relative change (%) | “-26 (0.006)” | “-27 (0.005)” | “-2” |
Visceral to subcutaneous adipose tissue ratio and spleen volume, final analysis (poster) and interim analysis (company release)
Comparable effects of lanifibranor alone and with empagliflozin
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Body weight, relative change from baseline to week 24, LS mean (95% CI) (registry)
| Measure | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
|---|---|---|---|
| Body weight, relative change (%) | “3.6 (2 to 5.19)” | “0.25 (-1.50 to 2.01)” | “-1.16 (-2.84 to 0.53)” |
Body weight with lanifibranor alone and with empagliflozin (poster and company release)
Mortality, serious adverse events, and selected other adverse events by arm (registry)
| Event, affected / at risk (%) | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
|---|---|---|---|
| All-cause mortality | “0/12 (0.00%)” | “0/13 (0.00%)” | “0/14 (0.00%)” |
| Other (not including serious) adverse events, total | “10/12 (83.33%)” | “9/13 (69.23%)” | “8/14 (57.14%)” |
| Serious adverse event: haematuria | “0/12 (0.00%)” | “1/13 (7.69%)” | “0/14 (0.00%)” |
| Anemia | “2/12 (16.67%)” | “0/13 (0.00%)” | “1/14 (7.14%)” |
| Oedema peripheral | “0/12 (0.00%)” | “1/13 (7.69%)” | “0/14 (0.00%)” |
| Headache | “2/12 (16.67%)” | “1/13 (7.69%)” | “0/14 (0.00%)” |
| Nausea | “1/12 (8.33%)” | “2/13 (15.38%)” | “0/14 (0.00%)” |
| Alopecia | “2/12 (16.67%)” | “0/13 (0.00%)” | “0/14 (0.00%)” |
| Diabetes mellitus inadequate control | “0/12 (0.00%)” | “2/13 (15.38%)” | “0/14 (0.00%)” |
| Blood glucose decreased | “0/12 (0.00%)” | “1/13 (7.69%)” | “1/14 (7.14%)” |
Tolerability statements by the company
Study limitations
Summary: sample size, early stop of recruitment, open-label arm, and multiplicity
- The protocol planned 63 participants (21 per group) for power close to 90%, assuming an HbA1c effect of 0.60% versus placebo. The protocol paused recruitment for an interim analysis once half of the planned participants were randomized; because the primary endpoint was met, recruitment was stopped. A total of 39 participants were treated (12 with lanifibranor, 13 with lanifibranor plus empagliflozin, and 14 with placebo) out of 213 screened.
- The lanifibranor and placebo arms were double-blind, and the lanifibranor plus empagliflozin arm was open-label.
- Treatment lasted 24 weeks, followed by a 4-week follow-up.
- No alpha adjustment was applied for the interim analysis, the protocol describing the trial as an “exploratory proof-of-concept study”, and no multiplicity adjustment was made for secondary endpoints.
- Inventiva does not expect to further study the combination of lanifibranor and empagliflozin.
Summary: population, endpoints, missing data, and figures that differ by source
- MASH was diagnosed by historical histology or noninvasive methods, including cT1 thresholds on LiverMultiScan with or without MRI-PDFF. Participants had type 2 diabetes with HbA1c of 7.0% to 10.0% on diet, metformin, and/or a DPP-4 inhibitor; current or recent treatment with GLP-1 receptor agonists, insulin, or sulfonylureas was excluded. In the poster, 35 of 39 participants (90%) were enrolled in the United States.
- The primary endpoint was the change in HbA1c; other endpoints were circulating biomarkers and MRI-based imaging.
- In the placebo arm, 9 of 14 participants completed treatment (2 withdrawals, 2 lost to follow-up, 1 noncompliance). Two participants without post-treatment HbA1c values were excluded from the MMRM analysis, which used no explicit imputation, and 16 participants without week 24 VAT/SAT values were excluded from that ANCOVA analysis. Data after an intercurrent event (rescue medication in 2 participants and a significant diet change in 1) were excluded.
- The interim analysis (FAS, n=11, 10, and 9) reported HbA1c changes of -1.14% and -1.59% with lanifibranor and the combination versus +0.26% with placebo; the final registry analysis reports -1.11, -1.54, and 0.16. The VAT/SAT ratio with placebo increased by 11% in the interim release and by 2% in the final poster. Completers in the combination arm are 11 in the poster and 12 in the registry participant flow.